Argus Research analyst David Toung maintains $Quest Diagnostics (DGX.US)$ with a buy rating, and adjusts the target price from $165 to $175.
According to TipRanks data, the analyst has a success rate of 63.8% and a total average return of 9.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Quest Diagnostics (DGX.US)$'s main analysts recently are as follows:
The firm's outlook on Quest Diagnostics has been positively influenced by the integration of LifeLabs, which is a key factor behind the revised guidance, as well as persisting high utilization trends. The firm holds a favorable view on Quest, highlighting its defensive qualities amid an election cycle and more secure estimates for the coming years.
Quest Diagnostics delivered a strong performance in their third-quarter results, surpassing expectations. The company also maintained its earnings forecast despite challenges posed by hurricanes, and provided an encouraging preliminary outlook for fiscal 2025.
The firm has increased its estimates following Quest Diagnostics' strong third-quarter outcomes and encouraging preliminary outlook for 2025. The company's earnings visibility is deemed to remain robust due to consistent underlying healthcare utilization trends, gains in market share, and a favorable mix.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
阿格斯分析師David Toung維持$奎斯特診療 (DGX.US)$買入評級，並將目標價從165美元上調至175美元。
根據TipRanks數據顯示，該分析師近一年總勝率為63.8%，總平均回報率為9.7%。
此外，綜合報道，$奎斯特診療 (DGX.US)$近期主要分析師觀點如下：
奎斯特診療的前景受到了LifeLabs整合的積極影響，這是修訂指引背後的關鍵因素之一，以及持續高利用率趨勢。 公司對奎斯特持有積極看法，強調其在選舉週期中的防禦特性以及未來幾年更爲安全的預估。
奎斯特診療在第三季度業績中表現強勁，超出預期。 儘管受到颶風帶來的挑戰，公司仍維持其盈利預測，併爲2025財年提供了令人鼓舞的初步展望。
在奎斯特診療強勁的第三季度業績和令人鼓舞的2025財年初步展望之後，公司已經提高了其預估。 由於醫療保健利用趨勢持續穩定、市場份額增加和有利的組合，公司的盈利可見度被認爲仍然強勁。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
